Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/25/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong John Didsbury?

John Didsbury

President and Chief Operating Officer and CSO

DARA BioSciences , Inc.

HQ Phone:  (919) 872-5578

Direct Phone: (919) ***-****direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

DARA BioSciences , Inc.

8601 Six Forks Road Suite 160

Raleigh, North Carolina,27615

United States

Company Description

DARA BioSciences Inc. of Raleigh, North Carolina, is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects...more

Background Information

Employment History

Founder and Chief Executive Officer

T3D Therapeutics Inc


Head of Strategy and Operations

GlaxoSmithKline plc


Assistant Professor of Medicine

Duke University


Scientist

Genentech , Inc.


Chief Executive Officer

Nuada Pharmaceuticals Inc


President and Chief Executive Officer

Drug Discovery Center of Innovation


Web References(98 Total References)


Board of Directors | T3D Therapeutics

www.t3dtherapeutics.com [cached]

John Didsbury, Ph.D.
President & CEO, Chairman of the Board Dr. Didsbury is a seasoned Executive Manager with over 26 years of experience within the pharmaceutical and biotechnology industries in both small and large public and private companies. Dr. Didsbury was President/COO/CSO of DARA BioSciences, Inc. (now Midatech Pharma US (NASDAQ:CM - MTP). At DARA he led the development of T3D-959 and directed all operations of the business, overseeing all finances, financing efforts, business development, human resources and administration and directing all drug discovery programs of the company in a CSO role. He played a key role in taking the company public in 2008 through a reverse merger. Prior to DARA, Dr. Didsbury served as CEO of Nuada Pharmaceuticals Inc. Prior to his tenure at Nuada Dr. Didsbury was Head of Strategy and Operations at GlaxoSmithKline, Inc. Previously, Dr. Didsbury served as Associate Director of Biology at Macronex, Inc., as Assistant Professor of Medicine at Duke University Medical Center and as a scientist at Genentech, Inc.


www.heraldsun.com

John Didsbury is CEO of T3D Therapeutics, a startup company that is seeking money to carry a diabetes candidate into studies as a treatment for Alzheimer's disease.
DURHAM - A Research Triangle Park drug development startup company is looking to raise money to further studies of a drug candidate that was originally targeted as a treatment for diabetes as a treatment for Alzheimer's disease. T3D Therapeutics CEO Dr. John Didsbury said the start-up company licensed a diabetes drug candidate from Dara BioSciences, a Raleigh-based pharmaceutical company focused on cancer supportive care products and on developing cancer treatments. Didsbury was formerly chief scientific officer at Dara. "It's been a personal mission of mine to identify and develop a breakthrough medicine for any disease, and this particular drug is the culmination of the search," Didsbury said of the drug candidate, which he said he believes could have multiple mechanisms for treating Alzheimer's. "It's a tough haul, but one that just requires perseverance and tenacity." Didsbury said there are "striking similarities" between diabetes and Alzheimer's. The company's drug candidate would work in multiple ways by regulating enzymes involved in Alzheimer's defects, he said. "It acts in a myriad of ways, and like I said, it regulates the levels of certain key enzymes that are involved in the pathophysiology of the disease," he said. Through T3D Therapeutics, Didsbury is looking to raise money to try to carry the diabetes drug that his company licensed from Dara into Phase 2 trials. Didsbury said the additional funding will allow the company to do some pre-clinical work, but they're still evaluating their financial strategy to figure out a way to pay for Phase 2 trials. He said company has applied for grants from the National Institutes of Health and other organizations.


www.ipwire.com

The T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound.
We believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications. Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program." DARA previously reported that it was actively seeking to out-license DB959 as part of its strategic plan to focus on the commercialization of oncology supportive care products. John Didsbury, Ph.D., Founder and Chief Executive Officer of T3D Therapeutics, commented, "The T3D Therapeutics team has a long history with DB959, and we plan to develop it as a transformational new therapy for the treatment of Alzheimer's disease. Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D expects DB959 will afford a multidimensional opportunity, with the potential to improve several Alzheimer's disease pathologies including addressing beta amyloid plaque issues. Positive improvements in disease pathologies such as neuro-inflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles, and insulin resistance / lowered cerebral glucose metabolism also are anticipated." Didsbury continued, "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies.


medicaldevicelicensing.com: Industry news

medicaldevicelicensing.com [cached]

RALEIGH, North Carolina, March 25 /PRNewswire/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of John Didsbury, Ph.D. as President and Chief Operating Officer.
Dr.... http://medicaldevicelicensing.com/redirs/news_rss/news/viewNewsML/611 http://medicaldevicelicensing.com/redirs/news_rss/news/viewNewsML/611


pharmalicensing.com: Industry news

pharmalicensing.com [cached]

RALEIGH, North Carolina, March 25 /PRNewswire/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of John Didsbury, Ph.D. as President and Chief Operating Officer.
Dr.... http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/611 http://pharmalicensing.com/redirs/news_rss/public/news/viewNewsML/611


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory